Colorectal Neoplasms

• 

  Subject Areas on Research

  • 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. 
  • 5-HTTLPR and use of antidepressants after colorectal cancer including a meta-analysis of 5-HTTLPR and depression after cancer. 
  • A Comparative Effectiveness Trial of Alternate Formats for Presenting Benefits and Harms Information for Low-Value Screening Services: A Randomized Clinical Trial. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. 
  • A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. 
  • A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) 
  • A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization. 
  • A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. 
  • A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. 
  • A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. 
  • A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. 
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A randomized pilot trial of a telephone-based couples intervention for physical intimacy and sexual concerns in colorectal cancer. 
  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 
  • A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. 
  • A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). 
  • A statistic for comparing two correlated markers which are prognostic for time to an event. 
  • AGA future trends report: CT colonography. 
  • APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. 
  • Abdominal- versus thigh-based reconstruction of perineal defects in patients with cancer. 
  • Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation. 
  • Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. 
  • Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry trade. 
  • Activating mutation in MET oncogene in familial colorectal cancer. 
  • Adapting a couple-based intimacy enhancement intervention to breast cancer: A developmental study. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. 
  • Adherence to physician recommendation to colorectal cancer screening colonoscopy among Hispanics. 
  • Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant therapy for colorectal cancer. 
  • Age-related vulnerabilities of older adults with colon adenomas: evidence from Project Prevent. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • American Cancer Society Colorectal Cancer Survivorship Care Guidelines. 
  • An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. 
  • An examination of racial differences in process and outcome of colorectal cancer care quality among users of the veterans affairs health care system. 
  • Analysis of colorectal cancer screening regimens. 
  • Animal models of human colorectal cancer: Current status, uses and limitations. 
  • Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. 
  • Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. 
  • Antioxidant and DNA methylation-related nutrients and risk of distal colorectal cancer. 
  • Artificial neural networks improve the accuracy of cancer survival prediction. 
  • Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. 
  • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 
  • Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. 
  • Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. 
  • Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors. 
  • Associations of red meat, fat, and protein intake with distal colorectal cancer risk. 
  • Barriers to full colon evaluation for a positive fecal occult blood test. 
  • Bcl10 is not a target for frequent mutation in human carcinomas. 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. 
  • Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. 
  • Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. 
  • Black tea consumption and risk of rectal cancer in Moscow population. 
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • CT during arterial portography: diagnostic pitfalls. 
  • Can screening older patients for cancer save lives? 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Cannabinoids and the gut. 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Capecitabine-induced chest pain relieved by diltiazem. 
  • Capsule Commentary on Goldman et al., Comparative Effectiveness of Multifaceted Outreach to Initiate Colorectal Cancer Screening in Community Health Centers: A Randomized Controlled Trial. 
  • Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. 
  • Caspase 3 in dying tumor cells mediates post-irradiation angiogenesis. 
  • Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. 
  • Characterization of sporadic colon cancer by patterns of genomic instability. 
  • Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. 
  • Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study. 
  • Choice of exposure scores for categorical regression in meta-analysis: a case study of a common problem. 
  • Cholestyramine feeding lowers number of colonic apoptotic cells in rat. 
  • Circulating levels of inflammatory cytokines and risk of colorectal adenomas. 
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. 
  • Clinical applications of PET in oncology. 
  • Clinical, pathologic, and economic parameters of laparoscopic colon resection for cancer. 
  • Clinically relevant changes in family history of cancer over time. 
  • Cognitive errors and logistical breakdowns contributing to missed and delayed diagnoses of breast and colorectal cancers: a process analysis of closed malpractice claims. 
  • Colonoscopic indirect lymphangiography in a canine model. 
  • Colorectal Cancer Screening Quality Measures: Beyond Colonoscopy. 
  • Colorectal Cancer Screening, Version 1.2015. 
  • Colorectal cancer risk perceptions and screening intentions in a minority population. 
  • Colorectal cancer screening and treatment: review of outcomes research. 
  • Colorectal cancer screening in young patients with poor health and severe comorbidity. 
  • Colorectal cancer screening, comorbidity, and follow-up in elderly patients. 
  • Colorectal cancer screening. 
  • Colorectal cancer survivors' needs and preferences for survivorship information. 
  • Colorectal cancer testing in the national Veterans Health Administration. 
  • Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. 
  • Colorectal cancer: national and international perspective on the burden of disease and public health impact. 
  • Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response. 
  • Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. 
  • Colorectal polyps: detection with low-dose multi-detector row helical CT colonography versus two sequential colonoscopies. 
  • Colorectal screening patterns and perceptions of risk among African-American users of a community health center. 
  • Common familial colorectal cancer linked to chromosome 7q31: a genome-wide analysis. 
  • Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. 
  • Comparison of rectal mucosal proliferation measured by proliferating cell nuclear antigen (PCNA) immunohistochemistry and whole crypt dissection. 
  • Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. 
  • Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. 
  • Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. 
  • Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting. 
  • Contemporary surgical options for metastatic colorectal cancer. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Cost-effectiveness of screening the average-risk population for colorectal cancer. 
  • Cost-effectiveness: definitions and use in the gastroenterology literature. 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Current immunotherapeutic strategies in colon cancer. 
  • Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. 
  • Cytoablative therapy with combined resection and cryosurgery for limited bilobar hepatic colorectal metastases. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Defining best supportive care. 
  • Depression in patients with colorectal cancer in Saudi Arabia. 
  • Designing effective vaccines for colorectal cancer. 
  • Detecting colorectal cancer in stool with the use of multiple genetic targets. 
  • Detection of APC mutations in fecal DNA from patients with colorectal tumors. 
  • Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue® low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. 
  • Detection of intestinal dysplasia using angle-resolved low coherence interferometry. 
  • Detection of proximal colorectal cancers through analysis of faecal DNA. 
  • Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. 
  • Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative. 
  • Development and biological evaluation of ⁹⁹mTc-sulfonamide derivatives for in vivo visualization of CA IX as surrogate tumor hypoxia markers. 
  • Development and initial testing of a computer-based patient decision aid to promote colorectal cancer screening for primary care practice. 
  • Development and quantitative evaluation of a high-resolution metabolomics technology. 
  • Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors. 
  • Dietary patterns differ between urban and rural older, long-term survivors of breast, prostate, and colorectal cancer and are associated with body mass index. 
  • Differences between univariate and bivariate models for summarizing diagnostic accuracy may not be large. 
  • Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-year population-based analysis. 
  • Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. 
  • Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma. 
  • Early diagnosis and prevention of sporadic colorectal cancer. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Economic burden for informal caregivers of lung and colorectal cancer patients. 
  • Ectopic expression of mucins in colorectal cancer metastasis. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Effect of Radiation Dose Reduction and Reconstruction Algorithm on Image Noise, Contrast, Resolution, and Detectability of Subtle Hypoattenuating Liver Lesions at Multidetector CT: Filtered Back Projection versus a Commercial Model-based Iterative Reconstruction Algorithm. 
  • Effects of communicating social comparison information on risk perceptions for colorectal cancer. 
  • Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficiency of colorectal cancer care among veterans: analysis of treatment wait times at Veterans Affairs Medical Centers. 
  • Electronic medical records and improving the quality of the screening process. 
  • Enrollment of patients with lung and colorectal cancers onto clinical trials. 
  • Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells. 
  • Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. 
  • Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. 
  • Examining potential colorectal cancer care disparities in the Veterans Affairs health care system. 
  • Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. 
  • Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. 
  • Five-year colon surveillance after screening colonoscopy. 
  • Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. 
  • Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). 
  • General performance on a numeracy scale among highly educated samples. 
  • Genetic instability of microsatellites in endometrial carcinoma. 
  • Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns. 
  • Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. 
  • Group trajectory analysis helps to identify older cancer survivors who benefit from distance-based lifestyle interventions. 
  • HER2 testing in metastatic colorectal cancer: ready for prime time? 
  • Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. 
  • Helicobacter pylori Biomarkers and Risk of Colorectal Oncogenesis--Response. 
  • Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. 
  • Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. 
  • Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). 
  • Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • High frequency of mutations of the PIK3CA gene in human cancers. 
  • High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer. 
  • Histological and molecular evaluation of patient-derived colorectal cancer explants. 
  • Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. 
  • How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. 
  • Human colonic sulfomucin identified by a specific monoclonal antibody. 
  • Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. 
  • Immunohistochemical analysis of statin in colorectal adenocarcinoma, polyps, and normal mucosa. 
  • Impact of comorbidity on colorectal cancer screening in the veterans healthcare system. 
  • Impact of functional support on health-related quality of life in patients with colorectal cancer. 
  • Impact of liver-directed therapy in colorectal cancer liver metastases. 
  • Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. 
  • Impact of simultaneous diaphragm resection during hepatectomy for treatment of metastatic colorectal cancer. 
  • Improving colorectal cancer screening and care in the Veterans Affairs Healthcare system. 
  • Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. 
  • Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. 
  • Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. 
  • Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. 
  • Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. 
  • Increasing colorectal cancer screening among individuals in the carpentry trade: test of risk communication interventions. 
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. 
  • Induction of cell stress through gene transfer of an engineered heat shock transcription factor enhances tumor immunogenicity. 
  • Influence of ATM function on telomere metabolism. 
  • Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release. 
  • Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. 
  • Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. 
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. 
  • Intraoperative pelvic brachytherapy for treatment of locally advanced or recurrent colorectal cancer. 
  • Intraportal injection of monoclonal antibody in nude mice bearing hepatic metastases. 
  • Invited comment on Warrier et al: hereditary colorectal cancer screening and management practices by colorectal surgeons. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • Is colorectal cancer surveillance cost-effective in patients with ulcerative colitis? 
  • Is obesity an advantage in patients with colorectal cancer? 
  • Is there a role for simultaneous hepatic and colorectal resections? A contemporary view from NSQIP. 
  • Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression. 
  • Laparoscopic colon resection for cancer--a favorable view. 
  • Laparoscopic resection for colon cancer: a favorable view. 
  • Laparoscopic staging for hepatobiliary carcinoma. 
  • Laparoscopic versus open resection of colorectal liver metastasis. 
  • Left hepatic trisectionectomy for hepatobiliary malignancy: results and an appraisal of its current role. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. 
  • Loss of PTPRM associates with the pathogenic development of colorectal adenoma-carcinoma sequence. 
  • Lymph nodes in colorectal carcinoma. The Poisson probability paradigm. 
  • Lymphatic mapping and sentinel node identification for colorectal cancer. 
  • MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. 
  • MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. 
  • Magnetic resonance histology. 
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. 
  • Management of peritoneal carcinomatosis from colorectal cancer. 
  • Manipulating perceptions of colorectal cancer threat: implications for screening intentions and behaviors. 
  • Measuring patient preferences for colorectal cancer screening using a choice-format survey. 
  • Men's knowledge and beliefs about colorectal cancer and 3 screenings: education, race, and screening status. 
  • Meta-analyses of colorectal cancer risk factors. 
  • Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
  • Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. 
  • Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. 
  • Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modifying attributions of colorectal cancer risk. 
  • Molecular approaches for colorectal cancer screening. 
  • Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Monoclonal antibody against human colonic sulfomucin: immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. 
  • Mortality and follow-up colonoscopy after colorectal cancer. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Muir-Torre syndrome. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicolor in vitro translation. 
  • Mutational analysis of the tyrosine phosphatome in colorectal cancers. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • Narratives that address affective forecasting errors reduce perceived barriers to colorectal cancer screening. 
  • Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. 
  • Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis. 
  • Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. 
  • Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. 
  • Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patient characteristics associated with the level of patient-reported care coordination among male patients with colorectal cancer in the Veterans Affairs health care system. 
  • Patient-reported quality of supportive care among patients with colorectal cancer in the Veterans Affairs Health Care System. 
  • Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era. 
  • Perioperative and oncologic outcomes of minimally invasive liver resection for colorectal metastases: A case-control study of 130 patients. 
  • Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer. 
  • Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. 
  • Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. 
  • Phase II study of didemnin B in advanced colorectal cancer. 
  • Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. 
  • Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. 
  • Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. 
  • Phase II study of gemcitabine in advanced colorectal adenocarcinoma. 
  • Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. 
  • Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. 
  • Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. 
  • Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. 
  • Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. 
  • Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. 
  • Phase II trial of fazarabine in advanced colorectal carcinoma. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II trial of intravenous melphalan in advanced colorectal carcinoma. 
  • Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. 
  • Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. 
  • Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). 
  • Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. 
  • Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. 
  • Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. 
  • Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: a report from the Childhood Cancer Survivor Study. 
  • Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. 
  • Presence and correlates of racial disparities in adherence to colorectal cancer screening guidelines. 
  • Primary care providers' needs and preferences for information about colorectal cancer survivorship care. 
  • Primary lesion location influences postoperative survival in patients with metastatic colorectal spinal lesions. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. 
  • Proliferative activity at colonic anastomoses as determined by statin. A nonproliferation-specific nuclear protein. 
  • Proliferative activity of colonic mucosa at different distances from primary adenocarcinoma as determined by the presence of statin: a nonproliferation-specific nuclear protein. 
  • Psychometric validation and reliability analysis of a Spanish version of the patient satisfaction with cancer-related care measure: a patient navigation research program study. 
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. 
  • Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs. 
  • Quantitative proteome analysis of colorectal cancer-related differential proteins. 
  • Race and colorectal cancer screening: a population-based study in North Carolina. 
  • Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. 
  • Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. 
  • Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. 
  • Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. 
  • Randomized trial showed requesting medical records with a survey produced a more representative sample than requesting separately. 
  • Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. 
  • Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration. 
  • Reach out to ENhancE Wellness in Older Cancer Survivors (RENEW): design, methods and recruitment challenges of a home-based exercise and diet intervention to improve physical function among long-term survivors of breast, prostate, and colorectal cancer. 
  • Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. 
  • Rectal mucosal ornithine decarboxylase activity is not a useful marker of risk for colorectal neoplasia. 
  • Rectovaginal examinations and human papillomavirus: can we decrease the risk of colorectal infection? 
  • Recurrent tumor after resection of hepatic metastases from colorectal carcinoma: location and time of discovery as determined by CT. 
  • Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. 
  • Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? 
  • Relationship of epithelial ovarian cancer to other malignancies within families. 
  • Relative quantification based on logistic models for individual polymerase chain reactions. 
  • Religious beliefs, practices, and health in colorectal cancer patients in Saudi Arabia. 
  • Reply to S.P.Sura et al. 
  • Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. 
  • Reproducibility and variability of the rectal mucosal proliferation index using proliferating cell nuclear antigen immunohistochemistry. 
  • Risk factors for advanced disease in colorectal cancer. 
  • Risk of Incident Colorectal Cancer and Death After Colonoscopy: A Population-based Study in Utah. 
  • Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. 
  • Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists. 
  • Screening flexible sigmoidoscopy using an upper endoscope is better tolerated by women. 
  • Screening for colorectal cancer. 
  • Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. 
  • Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. 
  • Self-affirmation moderates effects of unrealistic optimism and pessimism on reactions to tailored risk feedback. 
  • Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. 
  • Solid tumor second primary neoplasms: who is at risk, what can we do? 
  • Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. 
  • Staging of colorectal cancer: past, present, and future. 
  • Stigma, perceived blame, self-blame, and depressive symptoms in men with colorectal cancer. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. 
  • Surgical Resection of the Primary Tumor in Stage IV Colorectal Cancer Without Metastasectomy is Associated With Improved Overall Survival Compared With Chemotherapy/Radiation Therapy Alone. 
  • Surgical management of pulmonary metastases. 
  • Surveillance issues in inflammatory bowel disease: ulcerative colitis. 
  • Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. 
  • Symptoms, weight loss, and physical function in a lifestyle intervention study of older cancer survivors. 
  • Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management? 
  • Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. 
  • Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia. 
  • Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. 
  • Systemic markers of oxidative status and colorectal adenomatous polyps. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Tea consumption, apoptosis, and colorectal adenomas. 
  • Technology evaluation: CEA-TRICOM, Therion Biologics Corp. 
  • Testing different formats for communicating colorectal cancer risk. 
  • The accuracy and completeness for receipt of colorectal cancer care using Veterans Health Administration administrative data. 
  • The activity of RhoA is correlated with lymph node metastasis in human colorectal cancer 
  • The apolipoprotein E epsilon2 allele and aging-associated health deterioration in older males. 
  • The bottom line: offer the colorectal cancer screening test that you can deliver. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The cost-effectiveness of aspirin for chemoprevention of colorectal cancer. 
  • The diagnostic accuracy/efficacy of MRI in differentiating hepatic hemangiomas from metastatic colorectal/breast carcinoma: a multiple reader ROC analysis using a jackknife technique. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of comorbid illness on receipt of cancer screening by older people. 
  • The efficacy of tailored print materials in promoting colorectal cancer screening: results from a randomized trial involving callers to the National Cancer Institute's Cancer Information Service. 
  • The interrelationships between and contributions of background, cognitive, and environmental factors to colorectal cancer screening adherence. 
  • The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. 
  • The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. 
  • The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer with peritoneal surface disease. 
  • The role of glutathione S-transferase P1-1 in colorectal cancer: friend or foe? 
  • The role of hPMS1 and hPMS2 in predisposing to colorectal cancer. 
  • The sentinel node in colorectal carcinoma. Mapping technique, pathologic assessment, and clinical relevance. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The use of a proforma improves colorectal cancer pathology reporting. 
  • Thirty years of rectal cancer research: a brief history. 
  • Time is money for both the healthy and the sick. 
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. 
  • Transportation: a vehicle or roadblock to cancer care for VA patients with colorectal cancer? 
  • Treatment of advanced colorectal cancer. 
  • Treatment-related toxicity and supportive care in metastatic colorectal cancer. 
  • Trends in up-to-date status in colorectal cancer screening, North Carolina, 1998-2002. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Underuse and Overuse of Colonoscopy for Repeat Screening and Surveillance in the Veterans Health Administration. 
  • Urinary isothiocyanates; glutathione S-transferase M1, T1, and P1 polymorphisms; and risk of colorectal cancer: the Multiethnic Cohort Study. 
  • Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans. 
  • Use of pathway information in molecular epidemiology. 
  • Use of psychosocial support services among male Veterans Affairs colorectal cancer patients. 
  • Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial. 
  • Using NCCN clinical practice guidelines in oncology to measure the quality of colorectal cancer care in the veterans health administration. 
  • Utilization of hospital-based chaplain services among newly diagnosed male Veterans Affairs colorectal cancer patients. 
  • Validation of a questionnaire to assess self-reported colorectal cancer screening status using face-to-face administration. 
  • Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans. 
  • Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. 
  • Variability in resource use: diagnosing colorectal cancer. 
  • Variation in the cost of medications for the treatment of colorectal cancer. 
  • Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. 
  • Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. 
  • Vesicular stomatitis virus as a treatment for colorectal cancer. 
  • Virtual colonoscopy. 
  • What's new in general surgery: surgical oncology. 
  • Why information alone is not enough: behavioral economics and the future of genomic medicine. 
  • Wnt addiction of genetically defined cancers reversed by PORCN inhibition. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • miR-1269 promotes metastasis and forms a positive feedback loop with TGF-β. 
  • p38 MAPK in development and cancer. 
  • p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Gellad, Ziad F., Associate Professor of Medicine, Medicine, Gastroenterology
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Hyslop, Terry, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • Moorman, Patricia Gripka, Professor in Community and Family Medicine, Duke Cancer Institute
  • Olsen, Maren Karine, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology, Nuclear Medicine
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Yan, Hai, Henry S. Friedman Professor of Neuro-Oncology in the School of Medicine, Pathology
  • Yancy Jr., William Samuel, Associate Professor of Medicine, Medicine, General Internal Medicine
  • Zafar, Syed Yousuf, Associate Professor of Medicine, Medicine, Medical Oncology